The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
Henry Li
Employment or Leadership Position - Crown Bioscience
Dawei Chen
Employment or Leadership Position - Crown Bioscience
Sheng Guo
Employment or Leadership Position - Crown Bioscience
Jie Cai
Employment or Leadership Position - Crown Bioscience
Yiyou Chen
Consultant or Advisory Role - Crown Bioscience
Stock Ownership - Crown Bioscience
Jean-Pierre Wery
Employment or Leadership Position - Crown Bioscience
Stock Ownership - Crown Bioscience